Canopy Growth reported first-quarter fiscal 2027 results that modestly beat analyst expectations, with sales of $58.63 million, or CA$81.2 million, up 13% from a year earlier and slightly ahead of consensus estimates. The company posted a loss of 2 cents a share, or 3 Canadian cents, versus expectations for a loss of 4 cents, or 5 Canadian cents. Cannabis net revenue rose 14% to CA$65.1 million, led by a 22% increase in Canada medical cannabis revenue to CA$25.8 million and a 10% rise in Canada adult-use cannabis revenue to CA$29.7 million. Storz & Bickel sales increased 6% to CA$16.1 million. Adjusted gross margin improved to 31% from 25% a year earlier, while adjusted EBITDA loss narrowed to CA$3.2 million, improving by CA$4.7 million. CFO Tom Stewart said the integration of MTL Cannabis is expanding supply and revenue opportunities and that further improvement is expected in the second half of fiscal 2027 as that process is completed.